All News

Two studies were recently published that validated the use of the DecisionDx-SCC test as a tool for the treatment of cutaneous squamous cell carcinoma.

Developers launched a clinical laboratory-developed test version of Haystack MRD in late 2024 and are further expanding access for oncologists.

Both experimental models significantly improved upon historical clinical risk trial groups for patients with acute myeloid leukemia.

Declan Walsh, MD, highlighted the need for nutrition research to enhance oncology care.

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.

Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.

Being proactive and quickly identifying when a patient may need the supportive care team is the best way to integrate this field into whole-person care.

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with frontline recurrent or metastatic head and neck squamous cell carcinoma.

The Chemo Mouthpiece had favorable outcomes when used during and after treatment with chemotherapy among a range of patients with various types of cancer.

Geraldine O’Sullivan Coyne, MD, PhD, MRCPI, discusses how the START center may expand access to novel therapies for patients who reside in a community setting.

The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.

Tycel Phillips, MD, highlighted the need for new therapies for patients with MCL who have experienced relapse on previous lines of treatment.

Although radiotherapy was safe and well tolerated in patients with esophageal squamous cell carcinoma, more research is needed to confirm these results.

Tycel Phillips, MD, spoke about the impact the glofitamab CRL had on the landscape of bispecifics in lymphoma.

A meta-analysis did not find any correlation between pathologic complete response and overall survival or disease-free survival in patients with rectal cancer.

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.

Significantly improved survival was observed with oxaliplatin among patients aged 60 to 70 years with stage III CRC but not among those older than 70 years.

D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.

Peter Martin, MD, discusses the complexities of treating relapsed MCL after treatment with a BTK inhibitor.

The biomarker NLR may not be suitable for prognosis prediction in older patients with small cell lung cancer, according to findings from this real-world study.

Historical standards for H3K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Peter Martin, MD, discusses the shifting paradigm for treating fit, transplant-eligible patients with MCL.

The confirmed ORR was 40.0% in cohort 1A and 66.7% in cohort 1B of patients treated with sacituzumab tirumotecan/tagitanlimab for advanced NSCLC.

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.

The safety profile of carfilzomib, lenalidomide, and dexamethasone was tolerable in fit patients with newly diagnosed multiple myeloma.

A survey found that patients believed dermatologic AEs were more prevalent with anti-cancer therapies than what has been reported.

Induction chemotherapy may allow investigators to biologically select patients with a favorable prognosis who benefit most from chemoradiotherapy.

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.